Number of cases | Maximum intensity (eggs g-1) | Geometric mean intensity (eggs g-1) (95% CL) | ||||
---|---|---|---|---|---|---|
Non-intervention | Intervention | Non-intervention | Intervention | Non-intervention | Intervention | |
Baseline survey (October 1996) | ||||||
Negative | 22 | 194 | ||||
Positive | 154 | 380 | 1440 | 3340 | 90 (70–117) | 77 (65–92) |
Positive also at follow-up | 32 | 56 | 1403 | 1303 | 179 (101–318) | 99 (68–145) |
Follow-up survey* | ||||||
New cases | 1 | 5 | 420 | 25 | 420 | 11 (4–26) |
Positive pre-treatment | 32 | 56 | 300 | 1000 | 29 (20–42) | 20 (13–29) |
Survey 1 (1997/1998) | ||||||
New cases | 63 | 43 | 470 | 750 | 20 (14–30) | 11 (6–18) |
Positive at follow-up | 24 | 31 | 407 | 1103 | 24 (13–45) | 21 (12–38) |
Survey2 (1998/1999) | ||||||
New cases | 18 | 32 | 397 | 525 | 8 (4–14) | 11 (7–17) |
Positive at survey 1 | 36 | 35 | 1333 | 655 | 8 (5–13) | 20 (11–34) |
Survey 3 (1999/2000) | ||||||
New cases | 94 | 36 | 557 | 303 | 22 (17–28) | 9 (6–15) |
Positive at survey 2 | 45 | 40 | 1380 | 417 | 26 (16–42) | 21 (13–32) |
Survey 4 (2000/2001) | ||||||
New cases | 17 | 47 | 523 | 743 | 15 (7–32) | 9 (7–13) |
Positive at survey 3 | 78 | 45 | 2527 | 833 | 48 (32–72) | 29 (17–47) |